Ascletis announced that the Ganovo phase III clinical study won the top clinical research award at the 15th National Congress of Chinese Society of the Infectious Disease of the China Medical Association.

Professor Wei Lai, the Director of the Institute of Hepatology of Peking University, also the principal investigator of Ganovo's clinical trial, was pleased to accept this award based on a unanimous vote by a professional reviewing committee convened by top national experts.

The awarded paper won the highest scientific merits out of 577 conference papers submitted this year. Ganovo regimen demonstrated excellent results of a cure rate of 97 percent (SVR12) in genotype 1 non-cirrhotic patients, within 12-week treatment duration.

The National Congress of Chinese Society of the Infectious Disease is the largest and most influential academic conference in China.

It attracted more than 2,000experts and doctors who participated in the conference this year from July 26-29. The award further reinforces the medical community's confidence in Ganovo's excellent efficacy, better safety and tolerability, strong commitment to high quality drugs, and service to Chinese patients delivered by Ascletis as a local innovative biotech company.

The launching conference for Ganovo (Danoprevir sodium tablets), China's indigenous anti-hepatitis C innovative drug was held at the China National Convention Center days ago. Such move has helped breaking the monopoly of Chinese the hepatitis C small molecular antiviral drugs by the international pharmaceutical giants.

Such drug has been developed by Ascletis Pharmaceutical (Zhejiang) Co., Ltd., a company dedicated to the development and commercialization of innovative drugs against hepatitis C virus (HCV), AIDS (HIV) and hepatitis B virus (HBV). Ascletis currently has five programs of antiviral drug discovery and development.

Dou Xiaoguang, a professor at Shengjing Hospital of China Medical University, introduced the development process and characteristics of Ganovo (Danoprevir sodium tablets).

She mentioned that the efficacy, resistance barrier and safety of Danoprevir are more advantageous than the Generation I, bringing hope for cure for hepatitis C patients in China.